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HER 2 testing is a requirement for a significant proportion of gastro-oesophageal 
adenocarcinomas as response to Trastumuzab is dependent on positive 
expression1. However, expression of HER2 may vary significantly within a tumour 
and in a gastric resection specimen a threshold of 10% strong positive staining is 
regarded as positive while in biopsies, a cluster of 5 positive cells showing strong 
membranous staining is regarded as positive 2 Initial guidelines which were based on 
no specific evidence recommended “an adequate number of viable biopsy 
specimens (ideally 6-8) are required”3. The recently published BSG quality standards 
in upper gastrointestinal endoscopy4 have also recommended a minimum of 8 
biopsies. Reported concordance between biopsy and resection cases varies quite 
markedly in the literature between 45-85% 5-8. Two studies in particular, both 
published in 2015,  have focussed on how many biopsies are required to ensure 
maximum correlation between biopsies and the resected specimen. Ahn et al 9 
compared 702 paired  biopsy and resection cases. They found a high degree of 
biopsy heterogeneity, but using using ROC  analysis concluded that a minimum of 4 
biopsies were required to minimise discrepancy. Tominaga et al 10 used a different 
methodology by examining 84 gastric cancer resection cases and assessing 6 
“virtual biopsies”distributed evenly  through the luminal compartment of the tumour.  
They concluded that 5 biopsies would be sufficient for complete correlation with the 
gastrectomy specimen. Interestingly, they also showed preferential expression in the 
luminal and lateral aspects of the tumour.    
These studies provide vital evidence, but neither have considered the real world 
scenario where many of the biopsies which are taken do not contain viable tumour.  
The object of this audit study was to look at the actual number of targeted biopsies 
taken and determine how many of these fragments actually contain viable tumour 
(i.e. diagnostic). Our aims was to see if the minimum standard for the recommended 
number of biopsies is being adhered to, and more importantly, determine the 
minimum number of biopsies required to get diagnostic material and reach the 
recommended requirement for HER2 testing. 
Methods 
This audit was registered with the NUH Trust online  Clinical Audit system. 105 
consecutive cases of biopsy proven upper GI cancer during 2016 were retrieved using 
the Winpath laboratory information system.  Cases were diagnostic biopsies with a 
proven diagnosis of upper GI cancer.  We therefore did not include cases where the 
diagnosis of cancer had been missed, or not proven.  The cases were then reviewed 
and the following recorded: 
 The total number of endoscopic biopsies taken. 
 The total number of endoscopic biopsies containing viable tumour. 
 The total number of endoscopic biopsies containing necrotic tumour. 
 The anatomical location i.e. oesophageal or gastric.  
The total number of biopsies and percentage with viable tumour was calculated, which 
enabled determination of the number of biopsies required to be taken to establish a 
diagnosis of cancer. Further, the data was inspected to determine the number of 
biopsies required to yield 4 or 5 viable tumour fragments.  Further, the number of 
biopsies required for viable tumour fragments was also calculated mathematically. 
 
Results 
We assessed 105 diagnostic upper gastrointestinal biopsies. 35 cases (33%) met the 
minimum national standards of at least 8 biopsies. The relationship between total 
number of biopsies and viable tumour fragments is shown in table 1.  A total of 667 
biopsies were taken of which 471 yielded viable tumour. On average, the chance of 
getting viable tumour with a single biopsy is therefore around 70%, and there is a 30% 
chance of missing tumour with each biopsy. The chance of missing  tumour with 
multiple biopsies is therefore 0.3n etc.  This translates to a 97% chance of getting at 
least one viable tumour biopsy with 3 biopsies  
However, for optimal gastric HER 2 testing, evidence suggests that at least 4 or 
possibly 5 tumour biopsies are required. 70/105 (67%) of cases had at least 4 viable 
tumour biopsies, but only 47/105 (45%) had 5 or more.  
Inspection of our data showed that if only  4 biopsies were taken 7/15 had 4 biopsies 
with tumour, 7/14 with 5 biopsies, 9/12 with 6 biopsies, 16/17 with 7 biopsies (table 
2a).  Taking further biopsies beyond 7 did not appear to increase the likelihood of 
reaching 4 tumour viable biopsies. If however 5 viable tumour biopsies are required, 
at least 10 biopsies were required for greater than 90% chance of 5 viable biopsies 
(table 2b). Assuming a fixed probability for a viable tumour biopsy of 0.7 we have 
constructed a probability tree using the binomial distribution  to calculate a 90% 
chance of getting at least 4 viable tumour biopsies. This amounted to 8 biopsies being 
required for a 94% chance of obtaining at least  four viable tumour biopsies. With 
seven biopsies the probability of at least four viable tumour biopsies is less than 90%. 
This theoretical approach assumes a fixed probability for each biopsy and as a model 
system could be refined with the collection of more data. 
 
Discussion  
Trastuzumab (Herceptin) has become standard of care for first line chemotherapy in 
patients with metastatic gastro-oesophageal cancer for the small proportion of tumours 
which strongly express HER2 11. Most of these patients will have had biopsies only 
and will not have undergone prior gastrectomy. Recent studies 9,10 suggest that 4 or 5 
viable biopsies are required to reach optimal concordance for HER2 status between 
biopsy and gastrectomy specimen.   
This audit study was undertaken to determine how frequently we met this standard, 
and how many biopsies were required to be taken to reach this number. BSG 
guidelines recommend taking 8 tumour biopsies, but no evidence currently exists to 
support this 4.  
This audit has shown that in our centre which is likely to be representative of the UK 
in general, only 33% of all endoscopies met the required standard of 8 biopsies. 70% 
of targeted biopsies contained diagnosable cancer which all things being equal would 
translate to 3 biopsies being required for a 97% chance of diagnostic success.  Few 
previous studies have looked at this. Choi et al 12  in a prospective study showed very 
high diagnostic rates when 3-4 biopsies were taken in gastric and colorectal cancer 
but a previous study in rectal cancer showed less than 80% diagnostic rate in 
colorectal cancer with 6 biopsies 13  while an even older upper GI study recommended 
7 biopsies for a greater than 98%  chance of diagnosis 14.  
We are not aware of any studies which have looked at the optimal number of biopsies 
to be taken to ensure that the target of 4 or 5 viable tumour biopsies are collected for 
HER2 testing. The evidence here suggests that a minimum of 8 targeted biopsies 
should yield at least 4 viable tumour biopsies in more than 90% of cases while 5 viable 
biopsies requires at least 10 biopsies to be taken for a greater than 90% chance of 
success. Although there is some variation in the literature on the optimal number of 
viable biopsies needed, the current BSG upper GI quality standards guidelines 
recommendation of 8 biopsies now has solid evidence to support it. The German 
guidelines similarly recommend 8 biopsies be taken 15. 
 
 This study was limited by not including cases of intended tumour biopsy which did not 
yield a positive diagnosis at all and had to be repeated. However, it is likely that the 
same principle will apply to these cases and that taking at least 8 biopsies will avoid 
the requirement for repeat endoscopy other than in exceptional cases. It is likely that 
the biopsy yield for colorectal cancer will be even lower, as these tumours often have 
a large residual adenomatous component which may interfere with sampling the 
invasive component . It would certainly be worth doing a similar study on lower GI 
cancer. 
It is clear that there are multiple factors related to the chance of getting an adequate 
diagnostic biopsy. These include both tumour characteristics as well as endoscopist 
skill and experience. This study could not account for these factors, but gives a 
snapshot of actual practise in our institution where endoscopies are performed by a 
very wide range of individuals. The evidence presented here suggests that taking at 
least 8 biopsies will accomplish the task satisfactorily in the vast majority of cases.  
This study may also be of use to those planning the acquisition of fresh biopsy tissue 
for research, in particular the 100 000 genome project and other large studies seeking 
to obtain high quality genetic material. As mentioned, the chance of getting viable 
tumour with one targeted biopsy is no better than 70% so when harvesting upper GI 
tumour tissue for this purpose at least two and preferably 3 biopsies should be 
obtained.  
In summary, the results of this audit show that we are currently reaching the national 
guideline target in only a third of cases, and that only 67% of our cases had sufficient 
tumour tissue to accurately grade HER2 staining at the 4 viable tumour biopsy 
threshold (and only  45% at the 5 biopsy mark).  Furthermore, we have shown that 
taking at least 8 biopsies would likely increase our yield of required tissue to over 90%, 
supporting the national guidance. 
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Viable tumour present 




1 4 0 0 0 0 0 0 0 0 0 4 
2 1 3 0 0 0 0 0 0 0 0 4 
3 1 2 2 0 0 0 0 0 0 0 5 
4 3 3 2 7 0 0 0 0 0 0 15 
5 1 3 3 3 4 0 0 0 0 0 14 
6 2 0 1 3 5 1 0 0 0 0 12 
7 0 1 0 6 4 1 5 0 0 0 17 
8 0 1 0 2 1 0 1 5 0 0 10 
9 1 0 0 2 1 3 1 3 2 0 13 
10 0 0 0 0 0 1 0 1 2 0 4 
11 0 0 0 0 1 0 1 1 0 0 3 
12 0 0 1 0 0 2 0 0 0 0 3 
13 0 0 0 0 0 0 0 0 0 1 1 
Total 13 13 9 23 16 8 8 10 4 1 105 
Table 2 Relationship between number of biopsies and cases with >4 (table 2a) and 
>5 (table 2b) viable tumour fragments 
 
2a 
Total Number of biopsies Number of cases Number with >=4 tumour 
biopsies 
4 15 7  (47%) 
5 14 7  (50%) 
6 12 9  (75%) 
7 17 16 (94%) 
>=8 32 29 (91%) 
 
2b 
Total Number of biopsies Number of cases Number with >=5 tumour 
biopsies 
5 14 4  (29%) 
6 12 6  (50%) 
7 17 10 (59%) 
8 10 7 (70%) 
9 13 10 (77%) 









Figure 1 a: 5 gastric biopsies were taken. Only one (circled) shows cancer.  b:  
Another case with three biopsies taken; one is normal, one is necrotic tumor (blue 
circle) and only one is viable tumour (red circle) c: high power of viable tumour 
biopsy d: Her 2 staining on this case is negative (weak staining in benign epithelium) 
but not sufficient for a conclusive answer 
 
